Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Ofatumumab Improves Response Rates, PFS in Elderly/Unfit Patients With CLL

December 10th 2013

Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.

Dr. Flinn Discusses the Efficacy of IPI-145 in CLL

December 9th 2013

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

IPI-145 Has Activity in Relapsed/Refractory CLL

December 9th 2013

Almost half of patients with relapsed or refractory chronic lymphocytic leukemia attained objective responses when treated with an oral inhibitor of phosphoinositide-3-kinase-delta and -gamma.

Bcl-2 Inhibitor ABT-199 Shows Promise in CLL and SLL

December 9th 2013

ABT-199, an orally bioavailable selective inhibitor of the Bcl-2 protein as monotherapy, induced remissions in patients with relapsed/refractory CLL and SLL, including adverse-risk subsets of patients.

Obinutuzumab Regimen Slows CLL Compared With Rituximab

December 9th 2013

Patients with chronic lymphocytic leukemia and major comorbidities had significantly better outcomes when treated with the anti-CD20 monoclonal antibody obinutuzumab instead of rituximab.

Engineered T-Cells Achieve Dramatic Results in Resistant CLL

December 8th 2013

Treatment with engineered donor T cells led to substantial tumor regression in patients with posttransplant relapsed B-cell malignancies, results of a small clinical study showed.

Dr. Goede on Obinutuzumab Versus Rituximab in CLL

December 8th 2013

Valentin Goede, MD, from the University Hospital Cologne, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia with comorbidities.

Dr. Brown on Idelalisib Plus Rituximab in CLL

December 8th 2013

Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia.

Dr. Seymour on the Efficacy of ABT-199 in High-Risk CLL

December 8th 2013

John F. Seymour, MBBS, FRACP, PhD, discusses the efficacy of single-agent ABT-199 (GDC-0199), a novel Bcl-2 inhibitor, in high-risk relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

ASH 2013 Preview: CAR Modified T Cells, Novel Assays, and Ibrutinib

December 4th 2013

To gain insight into the studies being presented at the ASH Annual Meeting, we interviewed Marcel R.M. van den Brink, MD, PhD, on abstracts being presented by faculty at Memorial Sloan-Kettering Cancer Center.

Dr. van den Brink on Adding Ibrutinib to R-CHOP in NHL

December 4th 2013

Marcel R.M. van den Brink, MD, PhD, Head, discusses a trial being presented at the 2013 ASH Annual Meeting, analyzing the addition of ibrutinib to R-CHOP in patients with non-Hodgkin's lymphoma (NHL).

Lymphoma Research Focuses on Targeting Genetic Drivers

December 3rd 2013

During the past three decades, our treatment approach to lymphoma has been based on the underlying histological and clinical features of the disease.

Dr. Levis on the Challenges of Treating FLT3-ITD AML

November 27th 2013

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia (AML).

Novel Vaccine Induces Durable Remissions in Patients With Advanced Lymphoma

November 25th 2013

Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions.

Dr. Park on Vemurafenib in Hairy Cell Leukemia

November 18th 2013

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Memorial Hospital, discusses vemurafenib in hairy cell leukemia.

Dr. DeVita on Chemotherapy in Hodgkin's Lymphoma

November 11th 2013

Vincent T. DeVita, Jr, MD, Lymphoma: Giant of Cancer Care, Yale Cancer Center, discusses the use of chemotherapy for patients with Hodgkin's lymphoma.

Infinity Has High Hopes for PI3K Inhibitor

November 7th 2013

Infinity Pharmaceuticals of Cambridge, Massachusetts, began its efforts to produce innovative cancer treatments 12 years ago.

Drug Shortages Persist in Wake of Surveys

November 6th 2013

Headlines from the June meeting of the American Society of Clinical Oncology (ASCO) in Chicago announced to the general public what oncologists and hematologists have known for more than two years: sporadic shortages of cancer drugs are forcing suboptimal treatment plans for patients, and government efforts have not filled the void.

FDA Approves Frontline Obinutuzumab for CLL

November 1st 2013

The FDA has approved obinutuzumab plus chlorambucil as a first-line treatment for patients with chronic lymphocytic leukemia, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.

Ponatinib Manufacturer Suspends Distribution

October 31st 2013

Marketing and commercial distribution of ponatinib has been temporarily suspended, following an ongoing FDA investigation that revealed an increased frequency of arterial thrombosis and severe narrowing of the blood vessels.